

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

Amendments To The Claims:

1-198. (Canceled)

199. (New) A pharmaceutical composition comprising:

at least one first surface-building amphipathic substance selected from lipids, lipid-like materials and combinations thereof capable of forming bilayers;

at least one second surface-destabilising amphipathic substance selected from surface-active substances, surfactants and combinations thereof; and

at least one third amphipathic substance selected from insulin, interferon, interleukin, immunoglobulin and hormone;

wherein the composition is obtainable by steps comprising

selecting the at least one first and the at least one second substance,

combining the first and second substances in contact with the liquid medium to form substrates,

selecting the at least one third substance,

allowing the molecules of the third substance to associate with the substrate formed by the at least one first and the at least one second substance.

200. (New) The composition of claim 199 wherein the substrates are in the form of membrane surfaces.

201. (New) The composition of claim 199 wherein the substrate formed by the first and second substance carry a net electric charge and wherein the third substance carries a net

electric charge, the molecules of the third substance associating with the substrate, and the net charge density of the substrate and the net charge of the molecules associating with the substrate having the same sign.

202. (New) The composition of claim 199 wherein the substrates formed by the first and second substance are negatively charged and wherein the third substance is negatively charged.

203. (New) The composition of claim 199 wherein the first substance and the second substance differ in solubility on the average at least 10-fold.

204. (New) The composition of claim 199 wherein the first substance and the second substance differ in solubility on the average at least 100-fold.

205. (New) The composition of claim 199 wherein the first substance is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids, phosphatidylserines, sphingomyelins, sphingophospholipids, glycosphingolipids, cerebrosides, ceramidpolyhexosides, sulphatides, sphingoplasmalogenes, and gangliosides.

206. (New) The composition of claim 199 wherein the surfactant is selected from the group, consisting of long-chain fatty acids or long-chain fatty alcohols, alkyltrimethylammonium salts, alkyldimethyl-ammonium salts, alkylmethyl-ammonium salts, alkylsulphate salts, monovalent salts of cholate, deoxycholates, glycocholates, glycodeoxycholates, taurodeoxycholates, taurocholates, acyl dimethyl-aminoxides, alkanoyl dimethyl-aminoxides, dodecyl dimethyl-aminoxide, alkyl-N-methylglucamides, alkanoyl-N-methylglucamides, N-alkyl-N,N-dimethylglycines, 3-(acyldimethylammonio)-alkanesulphonates, N-acyl-sulphobetaines, polyethylen-glycol-octylphenyl ethers, nonaethylen-glycol-octylphenyl ether, polyethylene-acyl ethers, nonaethylen-dodecyl ether, polyethyleneglycol-isoacyl ethers, octaethyleneglycol-isotridecyl ether, polyethylene-acyl ethers, octaethylenedodecyl ether,

polyethyleneglycol-sorbitane-acyl esters, polyethyleneglykol-20-monolaurate (Tween 20), polyethyleneglykol-20-sorbitan-monooleate (Tween 80), polyhydroxyethylene-acyl ethers, polyhydroxyethylene-lauryl ethers, polyhydroxyethylene-myristoyl ethers, polyhydroxyethylene-cetylstearyl ethers, polyhydroxyethylene-oleoyl ethers, polyhydroxyethylen-4, or 6, or 8, or 10, or 12-lauryl ethers (Brij series), polyhydroxyethylen-8-stearate (Myrj 45), polyhydroxyethylen-laurates, polyhydroxyethylen-oleates, polyethoxylated castor oil 40 (Cremophor EL), sorbitane-monoalkylates, sorbitane-monolaurate, acyl-N-methylglucamides, alkanoyl-N-methylglucamides, decanoyl-N-methylglucamide, dodecanoyl-N-methylglucamide, alkyl-sulphates, alkyl sulphate saltslauryl-sulphate, oleoyl-sulphate, sodium deoxycholate, sodium glycodeoxycholate, sodium oleate, sodium taurate, fatty acid salts, sodium elaidate, sodium linoleate, sodium laurate, lysophospholipids, n-octadecylene-glycerophosphatidic acid, octadecylene-phosphorylglycerol, octadecylene-phosphorylserine, n-acyl-glycero-phosphatidic acids, lauryl glycero-phosphatidic acids, oleoyl-glycero-phosphatidic acid, n-acyl-phosphorylglycerol, lauryl-phosphorylglycerol, oleoyl-phosphorylglycerol, n-acyl-phosphorylserine, lauryl-phosphorylserine, oleoyl-phosphorylserine, n-tetradecyl-glycero-phosphatidic acid, n-tetradecyl-phosphorylglycerol, n-tetradecyl-phosphorylserine, corresponding palmitoeloyl-, elaidoyl-, vaccenyl-lysophospholipids, and surface-active polypeptides.

207. . (New) The composition of claim 199 wherein the at least one first substance is a phosphatidylcholine and/or a phosphatidylglycerol and the at least one second substance is a lysophospholipid, a lysophosphatidic acid, methylphosphatidic acid, lysophosphatidylglycerol, lysophosphatidylcholine, a partially N-methylated lysophosphatidylethanolamine, a monovalent salt of cholate, deoxycholate, glycocholate, glycodeoxycholate, or a sufficiently polar sterol derivative, a laurate, myristate, palmitate, oleate, palmitoleate, elaidate or other fatty acid salt and/or a Tween-, a Myrj-, or a Brij-surfactant, or a Triton, a fatty acid sulphonate, -sulphobetaine, -N-glucamide or -sorbitane surfactant.

208. . (New) The composition of claim 199 wherein the third substance is a hormone.

209. (New) The composition of claim 199 wherein the third substance is insulin selected from human recombinant insulin or humanized insulin.

210. (New) The composition of claim 199 wherein the third substance is interleukin suitable for the use in humans or animals selected from the group comprising IL-2, IL-4, IL-8, IL-10, and IL-12.

211. (New) The composition of claim 199 wherein the third substance is interferon selected from interferon alpha, beta and gamma.

212. (New) The composition of claim 199 wherein the third substance is immunoglobulin (Ig) selected from IgA, IgG, IgE, IgD or IgM.

213. (New). The composition of claim 208 wherein the hormone is calcitonin.

214. (New) The pharmaceutical composition of 199 wherein the composition is obtained by steps comprising:

selecting the at least one first and the at least one second substance,

combining the first and second substances in contact with the liquid medium to form the substrate,

selecting the at least one third substance,

allowing the molecules of the third substance to associate with the substrate formed by the at least one first and the at least one second substance.

215. (New) A method of producing a pharmaceutical composition comprising;

selecting at least one first and at least one second substance,

combining the first and second substances in contact with the liquid medium to form substrate,

selecting the at least one third substance,

allowing the molecules of the third substance to associate with the substrate formed by the at least one first and the at least one second substance, wherein;

at least one first surface-building amphipathic substance selected from lipids, lipid-like materials and combinations thereof capable of forming bilayers;

at least one second surface-destabilising amphipathic substance selected from surface-active substances, surfactants and combinations thereof; and

at least one third amphipathic substance selected from insulin, interferon, interleukin, immunoglobulin and hormone.

216. (New) The method of claim 215 wherein the first substance is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidylinositol, phosphatidic acids, phosphatidylserines, sphingomyelins, sphingophospholipids, glycosphingolipids, cerebrosides, ceramidpolyhexosides, sulphatides, sphingoplamalogenes, and gangliosides.

217. (New) The method of claim 215 wherein the surfactant is selected from the group, consisting of long-chain fatty acids or long-chain fatty alcohols, alkyltrimethylammonium salts, alkyldimethyl-ammonium salts, alkylmethyl-ammonium salts, alkylsulphate salts, monovalent salts of cholate, deoxycholates, glycocholates, glycodeoxycholates, taurodeoxycholates, taurocholates, acyl dimethyl-aminoxides, alkanoyl dimethyl-aminoxides, dodecyl dimethyl-aminoxide, alkyl-N-methylglucamides, alkanoyl-N-methylglucamides, N-alkyl-N,N-dimethylglycines, 3-(acyldimethylammonio)-alkanesulphonates, N-acyl-sulphobetaines, polyethylen-glycol-octylphenyl ethers, nonaethylen-glycol-octylphenyl ether, polyethylene-acyl ethers, nonaethylen-dodecyl ether, polyethyleneglycol-isoacyl ethers, octaethyleneglycol-isotridecyl ether, polyethylene-acyl ethers, octaethylenedodecyl ether, polyethyleneglycol-sorbitane-acyl esters, polyethylenglykol-20-monolaurate (Tween 20), polyethylenglykol-20-sorbitan-monooleate (Tween 80), polyhydroxyethylene-acyl ethers, polyhydroxyethylene-lauryl ethers, polyhydroxyethylene-myristoyl ethers, polyhydroxyethylene-cetylstearyl ethers, polyhydroxyethylene-oleoyl ethers, polyhydroxyethylen-4, or 6, or 8, or 10, or 12-lauryl ethers (Brij series), polyhydroxyethylen-8-stearate (Myrj 45), polyhydroxyethylen-

laurates, polyhydroxyethylen-oleates, polyethoxylated castor oil 40 (Cremophor EL), sorbitane-monoalkylates, sorbitane-monolaurate, acyl-N-methylglucamides, alkanoyl-N-methylglucamides, decanoyl-N-methylglucamide, dodecanoyl-N-methylglucamide, alkyl-sulphates, alkyl sulphate saltslauryl-sulphate, oleoyl-sulphate, sodium deoxycholate, sodium glycodeoxycholate, sodium oleate, sodium taurate, fatty acid salts, sodium elaidate, sodium linoleate, sodium laurate, lysophospholipids, n-octadecylene-glycerophosphatidic acid, octadecylene-phosphorylglycerol, octadecylene-phosphorylserine, n-acyl-glycero-phosphatidic acids, lauryl glycero-phosphatidic acids, oleoyl-glycero-phosphatidic acid, n-acyl-phosphorylglycerol, lauryl-phosphorylglycerol, oleoyl-phosphorylglycerol, n-acyl-phosphorylserine, lauryl-phosphorylserine, oleoyl-phosphorylserine, n-tetradecyl-glycero-phosphatidic acid, n-tetradecyl-phosphorylglycerol, n-tetradecyl-phosphorylserine, corresponding palmitoeloyl-, elaidoyl-, vaccenyl-lysophospholipids, and surface-active polypeptides.

218. (New) The method of claim 215 wherein the at least one first substance is a phosphatidylcholine and/or a phosphatidylglycerol, the at least one second substance is a monovalent salt of cholate, deoxycholate, glycocholate, glycodeoxycholate, and/or a Tween-surfactant, and the at least one third substance is insulin.

219. (New) The method of claim 215 wherein the third substance is a hormone.

220. (New) The method of claim 219 wherein the hormone is calcitonin.

221. (New) The method of claim 215 wherein the third substance is insulin selected from human recombinant insulin or humanized insulin.

222. (New) The method of claim 215 wherein the third substance is interleukin suitable for the use in humans or animals selected from the group comprising IL-2, IL-4, IL-8, IL-10, and IL-12.

223. (New) The method of claim 215 wherein the third substance is interferon selected from interferon alpha, beta and gamma.

224. (New) The method of claim 215 wherein the third substance is immunoglobulin (Ig) selected from IgA, IgG, IgE, IgD or IgM.